Provided by Tiger Fintech (Singapore) Pte. Ltd.

SELLAS Life Sciences Group Inc.

1.21
+0.130012.04%
Post-market: 1.220.0100+0.83%19:59 EDT
Volume:972.60K
Turnover:1.14M
Market Cap:95.08M
PE:-1.89
High:1.22
Open:1.11
Low:1.09
Close:1.08
Loading ...

The Smartest Growth Stock to Buy With $1,000 Right Now

Motley Fool
·
Yesterday

Tom's of Maine Introduces Whiten+ Toothpaste: Natural, Effective Whitening

PR Newswire
·
05 Mar

NASA May Cancel Boeing's Big $82 Billion Space Opportunity

Motley Fool
·
23 Feb

Blue Origin Prepares for Layoffs. Here's What Space Stock Investors Need to Know

Motley Fool
·
22 Feb

Boeing to Cut 400 Jobs on NASA's SLS Moon Rocket Program

MT Newswires Live
·
10 Feb

Largest borrow rate increases among liquid names

TIPRANKS
·
03 Feb

Sellas $25M registered direct offering priced at $1.27 per share and warrant

TIPRANKS
·
29 Jan

Sellas Life Sciences Group Announces $25 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

THOMSON REUTERS
·
29 Jan

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire
·
29 Jan

SELLAS Life Sciences Shares Fall; Interim Trial Results on Acute Myeloid Leukemia Treatment Issued

MT Newswires Live
·
24 Jan

Sellas Life Sciences announces IDMC completed interim analysis of REGAL trial

TIPRANKS
·
23 Jan

Sellas Life Sciences Group Inc: 80% of Randomly Selected Regal Gps Patients Showed a Specific T-Cell Immune Response

THOMSON REUTERS
·
23 Jan

Sellas Life Sciences Group: Idmc Has Recommended That Trial Continue Without Modifications

THOMSON REUTERS
·
23 Jan

Sellas Life Sciences Announces Positive Outcome of Interim Analysis for Its Pivotal Phase 3 Regal Trial of Gps in Acute Myeloid Leukemia

THOMSON REUTERS
·
23 Jan

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

GlobeNewswire
·
23 Jan

BRIEF-Sellas Life Sciences Says Full Topline Phase 2 Data In Acute Myeloid Leukemia And FDA Regulatory Review Expected In 1H 2025 For SLS009

Reuters
·
08 Jan